Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9863750 | 0.81 | ALOX15 (0.53) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| SCHEMBL4652514 | 0.81 | ALOX15 (0.53) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| SCHEMBL24784588 | 0.81 | HDAC1 (0.55) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| SCHEMBL12827256 | 0.81 | CYP11B1 (0.55) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| SCHEMBL5542313 | 0.81 | ALOX15 (0.53) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| SCHEMBL2292334 | 0.80 | APP (0.44) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL9512459 | 0.79 | ALOX15 (0.52) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| SCHEMBL14382237 | 0.78 | HDAC1 (0.53) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| SCHEMBL10184678 | 0.78 | HDAC1 (0.56) | ALOX15TSHRCASP1CYP11B1CYP11B2 | |
| SCHEMBL5535861 | 0.78 | HDAC1 (0.52) | ALOX15TSHRCASP1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| EP-3515447-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | Tufts University (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018058148-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018058148-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| EP-1644320-B1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7265246-B2 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1644320-A1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1578735-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | Pfizer Limited (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005009941-A1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | CHRM1, CHRM3, CHRM2 | ALOX15 2624/4885TSHR 105/4885CASP1 3050/4885 |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | ALOX15 1575/4885TSHR 3192/4885CASP1 1732/4885 |
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | ALOX15 1475/4885TSHR 3680/4885CASP1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.